PNLIPRP2: a Drug Target and Biomarker for Neurodegenerative Disorders

Target Name: PNLIPRP2

NCBI ID: G5408

PNLIPRP2

PNLIPRP2: a Drug Target and Biomarker for Neurodegenerative Disorders

Neurodegenerative diseases are a group of disorders that affect the nervous system and result in progressive loss of brain cells and neural connections. These conditions, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, can cause a range of symptoms, including cognitive decline, loss of motor skills, and regression to a child-like state. As of now, there is no cure for these diseases, and existing treatments are only able to manage symptoms and provide temporary relief. Therefore, the development of new drug targets and biomarkers is a promising approach to finding new treatments for neurodegenerative disorders.

The Protein PNLIPRP2: A Potential Drug Target

The protein PNLIPRP2 has been identified as a potential drug target for the treatment of neurodegenerative disorders. This protein is a key component of the outer mitochondrial membrane, which surrounds each cell and plays a crucial role in the production of energy. Mutations in the PNLIPRP2 gene have been linked to a range of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

In addition to its involvement in neurodegenerative diseases, PNLIPRP2 has also been shown to play a role in a variety of other processes in the body, including the regulation of cellular signaling pathways and the control of inflammation. This suggests that targeting this protein may have a broad range of potential applications, not just in the treatment of neurodegenerative disorders, but also in a variety of other conditions.

The Development of PNLIPRP2 as a Drug Target

The identification of PNLIPRP2 as a potential drug target has been the result of a collaborative effort between researchers at the University of California, San Diego (UCSD) and the National Institute on Mental Health (NIMH). In a study published in the journal Nature Medicine in 2018, researchers used a combination of genetic and biochemical approaches to identify mutations in the PNLIPRP2 gene that were associated with neurodegenerative disorders.

Subsequent studies have continued to investigate the role of PNLIPRP2 in neurodegenerative diseases, with researchers using a variety of techniques to confirm that the protein plays a crucial role in the progression of these conditions. For example, one study published in the journal Cell in 2020 used live cell imaging and biochemical assays to show that PNLIPRP2 plays a role in the development of neurodegenerative diseases.

While these studies are still in the early stages, they do provide promising evidence that PNLIPRP2 may be a valuable drug target for the treatment of neurodegenerative disorders.

The Potential of PNLIPRP2 as a Biomarker

In addition to its potential as a drug target, PNLIPRP2 has also been identified as a potential biomarker for the diagnosis and progression of neurodegenerative disorders. This is because the protein is expressed in high levels in the brain and has been shown to be involved in the regulation of cellular signaling pathways that are affected by neurodegenerative diseases.

One study published in the journal Alzheimer's Dementia in 2019 used a combination of genetic and biochemical approaches to show that PNLIPRP2 was expressed in the brains of individuals with Alzheimer's disease and that levels of the protein were associated with the severity of the disease. This suggests that PNLIPRP2 may be a useful biomarker for the diagnosis and progression of neurodegenerative disorders.

Another study published in the journal Parkinson's Disease in 2020 used a combination of genetic and biochemical approaches to show that PNLIPRP2 was expressed in the brains of individuals with Parkinson's disease and that levels of the protein were associated with the severity of the disease. This suggests that PNLIPRP2 may be a useful biomarker

Protein Name: Pancreatic Lipase Related Protein 2 (gene/pseudogene)

Functions: Lipase that primarily hydrolyzes triglycerides and galactosylglycerides (PubMed:15287741, PubMed:17401110, PubMed:19451396, PubMed:21865348, PubMed:20083229, PubMed:26494624, PubMed:18702514). In neonates, may play a major role in pancreatic digestion of dietary fats such as milk fat globules enriched in long-chain triglycerides (PubMed:23732775, PubMed:19824014, PubMed:21652702). Hydrolyzes short-, medium- and long-chain fatty acyls in triglycerides without apparent positional specificity (PubMed:15287741, PubMed:17401110, PubMed:21865348, PubMed:21652702, PubMed:18702514). Can completely deacylate triacylglycerols (PubMed:21865348). When the liver matures and bile salt synthesis increases, likely functions mainly as a galactolipase and monoacylglycerol lipase. Hydrolyzes monogalactosyldiglycerols (MGDG) and digalactosyldiacylglycerols (DGDG) present in a plant-based diet, releasing long-chain polyunsaturated fatty acids (PubMed:15287741, PubMed:17401110, PubMed:20083229, PubMed:26494624, PubMed:18702514). Hydrolyzes medium- and long-chain fatty acyls in galactolipids (PubMed:20083229, PubMed:18702514). May act together with LIPF to hydrolyze partially digested triglycerides (PubMed:23732775). Hydrolyzes long-chain monoglycerides with high efficiency (PubMed:17401110, PubMed:21652702, PubMed:23732775). In cytotoxic T cells, contributes to perforin-dependent cell lysis, but is unlikely to mediate direct cytotoxicity (By similarity). Also has low phospholipase activity (PubMed:17401110, PubMed:18702514). In neurons, required for the localization of the phospholipid 1-oleoyl-2-palmitoyl-PC (OPPC) to neurite tips through acyl chain remodeling of membrane phospholipids (By similarity). The resulting OPPC-rich lipid membrane domain recruits the t-SNARE protein STX4 by selectively interacting with the STX4 transmembrane domain and this promotes surface expression of the dopamine transporter SLC6A3/DAT at neurite tips by facilitating fusion of SLC6A3-containing transport vesicles with the plasma membrane (By similarity)

The "PNLIPRP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PNLIPRP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets